ストックスクリーナーアプリを入手
6.995
64.49%
-12.70
アフターアワーズ：
6.90
-0.095
-1.36%
前日終値:
$19.70
開ける：
$5.865
24時間の取引高:
29.97M
Relative Volume:
17.29
時価総額：
$405.09M
収益：
$11.13M
当期純損益:
$-114.59M
株価収益率:
-3.0242
EPS:
-2.313
ネットキャッシュフロー:
$-113.96M
1週間 パフォーマンス:
-64.13%
1か月 パフォーマンス:
-73.54%
6か月 パフォーマンス:
-70.26%
1年 パフォーマンス:
-0.92%
1日の値動き範囲:
$5.82
$7.85
1週間の範囲:
$5.82
$20.54
52週間の値動き範囲:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
名前
Capricor Therapeutics Inc
セクター
電話
(310) 358-3200
住所
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
6.995 | 1.14B | 11.13M | -114.59M | -113.96M | -2.313 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-30 | 開始されました | Alliance Global Partners | Buy |
| 2025-06-26 | 開始されました | B. Riley Securities | Buy |
| 2025-05-20 | 開始されました | Roth Capital | Buy |
| 2024-10-21 | 開始されました | Piper Sandler | Overweight |
| 2024-05-17 | 開始されました | Oppenheimer | Outperform |
| 2024-01-05 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-12-26 | ダウングレード | Maxim Group | Buy → Hold |
| 2018-01-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-09-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-02-13 | 再開されました | Rodman & Renshaw | Buy |
| 2016-07-06 | 再開されました | H.C. Wainwright | Buy |
| 2016-06-15 | 開始されました | ROTH Capital | Buy |
すべてを表示
Capricor Therapeutics Inc (CAPR) 最新ニュース
CAPR Investor Alert: Kehoe Law Firm, P.C. Investigates Capricor T - The National Law Review
UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy - BioSpace
FDA staff report throws cold water on Capricor's DMD cell therapy bid - FirstWord Pharma
Capricor Therapeutics (NASDAQ:CAPR) Stock Rating Lowered by Roth Capital - MarketBeat
CAPR Stock On Track For Worst Day Ever — Analysts Divided On Deramiocel’s Approval Probability After FDA Documents Paint ‘Ugly Picture’ - Stocktwits
Capricor Therapeutics stock falls after FDA briefing ahead of AdCom By Investing.com - Investing.com Australia
Capricor Therapeutics stock falls after FDA briefing ahead of AdCom - Investing.com
Investigation launched into Capricor Therapeuti... - Pluang
Market movers: Nvidia, Advanced Micro Devices, Capricor Therapeutics, SpaceX… - Proactive financial news
Capricor stock plunges 70% after FDA questions trial data for heart therapy. - Pluang
Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel - GlobeNewswire
Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel - GlobeNewswire Inc.
CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC - GlobeNewswire
H.C. Wainwright reiterates Capricor stock Buy rating at $60 target - Investing.com
Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Benzinga
FDA briefing casts doubt on Capricor's deramiocel ahead of D - AllSci
Capricor Therapeutics faces securities fraud pr... - Pluang
B.Riley downgrades Capricor stock on FDA briefing concerns - Investing.com
BREAKING: Capricor Therapeutics Investigated for Securities - GlobeNewswire
Capricor Therapeutics’ 67.7% collapse and the warning signs that preceded it - Investing.com
$Capricor Therapeutics (CAPR.US)$ waaa hit my first 🎯 - Moomoo
Capricor Therapeutics (NASDAQ:CAPR) Receives Neutral Rating from B. Riley Financial - MarketBeat
Capricor Therapeutics (CAPR) Shares Plunge 67% After FDA Briefin - GuruFocus
B.Riley downgrades Capricor stock on FDA briefing concerns By Investing.com - Investing.com Canada
FDA scientists question Capricor data; Legend CEO steps down - BioPharma Dive
Capricor Therapeutics (CAPR) Downgraded as FDA Briefing Raises Approval Concerns - GuruFocus
Capricor Therapeutics (NASDAQ:CAPR) shares tumble 67% after FDA raises concerns over Deramiocel data - TechStock²
Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document - Stocktwits
Oppenheimer reiterates Capricor stock rating ahead of FDA panel By Investing.com - Investing.com South Africa
Capricor addresses FDA briefing materials ahead of advisory meeting By Investing.com - Investing.com South Africa
FDA staff flags data concerns about Capricor's therapy; shares plunge - Reuters
Capricor Therapeutics stock tumbles after FDA briefing documents - Investing.com
Capricor updates ahead of FDA advisory meeting on Duchenne muscular dystrophy therapy Deramiocel. - Pluang
Capricor Provides Update on Deramiocel for DMD Ahead of FDA Meeting - Intellectia AI
Capricor Therapeutics Provides Update Ahead of FDA Advisory Committee Meeting on Deramiocel BLA for Duchenne Muscular Dystrophy - Quiver Quantitative
Capricor Therapeutics (CAPR) Shares Plunge Amid FDA Data Concerns, GF Score™ at 28 - GuruFocus
Capricor shares drop 67% after FDA questions Du... - Pluang
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel - Yahoo Finance
Capricor plunges on FDA AdCom briefing doc for Duchenne treatment - Seeking Alpha
Capricor Therapeutics shares plunge after FDA releases briefing documents - Yahoo Finance
FDA staff flags concerns about Capricor’s Duchenne heart disease therapy - 1470 & 100.3 WMBD
Capricor Therapeutics Stock Plunges After FDA Releases Briefing Documents - Benzinga
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug - STAT
FDA staff flags concerns for Capricor’s Duchenne heart disease therapy - whbl.com
Capricor Therapeutics Inc (CAPR) Cash Flow - TradingKey
Capricor Therapeutics stock tumbles after FDA briefing documents By Investing.com - Investing.com South Africa
How FDA‑Linked HQ and Manufacturing Expansion At Capricor Therapeutics (CAPR) Has Changed Its Investment Story - Yahoo Finance
SpaceX Stock Price Today | SPCX Ticker, News, Retail Sentiment - Stocktwits
Capricor Therapeutics shares tumble after FDA reviewers raise concerns over Duchenne therapy - Proactive financial news
Is Capricor Therapeutics (CAPR) Trading At A Discount After Its Lease Deal And FDA Wait? - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Capricor Therapeutics Inc (CAPR) 財務データ
収益
当期純利益
現金流量
EPS
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):